

CARTopiaX: Extending a Next-Generation Platform for Computational Cancer Biology


Progress update of Google Summer of Code Project 2026



Author: Salvador de la Torre Gonzalez

Mentors: Luciana Melina Luque, Vassil Vassilev, Lukas Breitwieser

CAR T-cell Therapy



CAR T-cell therapy: A type of immunotherapy that engineers T-cells to recognize and kill cancer cells.

Image ref:

<https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy>

CAR-T Treatment Modeling: CARTopiaX

- While CAR-T therapy is **highly effective in hematological cancers** (e.g., leukemia) and supported by numerous mathematical models, it still **struggles in solid tumors**, where robust simulation **models remain scarce** despite their importance for optimizing treatment strategies.
- **CARTopiaX** is an **agent-based model** (ABM) built on [BioDynaMo](#), implementing the **mathematical framework** proposed in Nature [paper](#) “*In silico study of heterogeneous tumour-derived organoid response to CAR T-cell therapy*” (2024)
- It provides a platform for simulating **tumor-immune interactions**, **testing hypotheses** and **evaluating CAR-T treatment strategies in silico**.
- Goal: Extend and calibrate CARTopiaX to **reproduce state-of-the-art CAR T-cell experiments**, **demonstrating** it as a **flexible** and **robust framework** for in silico hypothesis testing that **accelerates research** and **reduces reliance on costly wet-lab** experiments.



Created in BioRender.com bio




The Selected Paper: Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model

- Experimental Setup: The study utilized HER2+ SKOV3 **ovarian cancer cells** in a 3-D GelMA hydrogel, comparing a **hypoxic environment** (created by a **polycarbonate cap**) **against normoxia** (no cap).
- Treatment Protocol: **Anti-HER2 CAR-T cell** efficacy was evaluated at a **20:1 effector-to-target (E:T) ratio** over a total experimental duration of **72 hours**.
- Limited T Cell Infiltration: Despite high tumor mortality, CAR-T cell infiltration into the 3-D hydrogel bulk was negligible, with most immune cells remaining at the edges.
- Key Finding, Bystander Killing Mechanism: **Tumor death at a distance (in the core)** was driven by metabolic competition; activated **CAR-T cells at the periphery** rapidly consume glucose and oxygen, **starving the already stressed cancer cells in the center**.
- Aim: Extend CARTopiaX to **replicate their results** in silico.







Ando Y, Sieglar EL, Ta HP, Cinay GE, Zhou H, Gorrell KA, Au H, Jarvis BM, Wang P, Shen K. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model. *Adv Healthc Mater*. 2019 Mar;8(5):e1900001. doi: [10.1002/adhm.201900001](https://doi.org/10.1002/adhm.201900001). Epub 2019 Feb 8. PMID: 30734529; PMCID: PMC6448565.


The model: cylindrical tumor mass




Data obtention



Area normalization
of the absolute
numbers





Number of cells computation





normoxia



hypoxia





Density of 10 million cells/mL, no cup (normoxia)



Absolute count is misleading: deaths are uniformly distributed



Anomalies caused by near-zero values and a very small radius containing too few cells





Density of 10 million cells/mL, with cup (hypoxia)

Paper's reported oxygen levels (orange).
The authors also modeled them using a
simple differential equation model (blue),
but this is unrelated to CARTopiaX

**Decreasing oxygen that flows
from the border of the cylinder
(3000 μ m)**





Density of 10 million cells/mL, with cup (hypoxia)





Cells tend to die at the center, where oxygen levels are lower



Anomalies caused by near-zero values and a very small radius containing too few cells



Density of 1 million cells/mL



Very few cells are present. Therefore, both the normoxic (without cup) and hypoxic (with cup) conditions **are effectively normoxic**, resulting in **no significant differences**.



Conclusion: Next steps & Impact

- Already achieved: **Hypoxic tumor** model successfully **replicated**.
- Present: Replicating the behavior of a **20:1 CAR T-cell therapy (already in progress)**, including:
 - A new **glucose** gradient.
 - **Medium viscosity** and its effect on CAR T-cell motility and interaction forces.
 - CAR T-cell **cytotoxicity** and **tumor immune evasion** under hypoxia.
 - Activated CAR T-cell **oxygen consumption**.
- Main goal: Establish **CARTopiaX** as a **flexible and extensible framework** for computational oncology.
- Further step: Already planning the **structure of a manuscript** presenting CARTopiaX through quantitative validation against wet-lab experiments for **publication in a scientific journal**.

